Amferia key facts
as of Oct 2026- Developer of medical devices designed for the global antibiotic resistance crisis.
- Amferia is valued at approximately $8.9M as of Oct 2026 (last reported valuation).
- It has raised $7.9M; the latest was Later Stage VC ($3.5M) in Dec 2025.
- Notable investors include European Union, Almi Invest, Chalmers Ventures, Alexander Hars, British Corinthian Properties — 10 tracked in total.
- Status: Privately Held (backing).
Amferia's last reported valuation, Sep 2024. Nothing priced has surfaced since.
- ·Watch Amferia: the Monday email on marks, rounds and moves
Amferia funding rounds
No funding rounds for Amferia are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
Amferia valuation
Amferia's last reported valuation was $8.9 million in Sep 2024. No priced round, secondary trade or fund mark has surfaced since.
Amferia investors
10 investors are on record for Amferia, including European Union, Almi Invest, Chalmers Ventures and Alexander Hars.
About Amferia
Developer of medical devices designed for the global antibiotic resistance crisis. The company develops and markets medical devices, emphasising antibacterial products that effectively kill bacteria when used in medical applications, such as wound care, enabling patients to prevent bacterial skin infections, including antibiotic-resistant infections, and for healthcare professionals to enhance infection control and improve patient outcomes.
- Sector
- Healthcare
- HQ
- Molndal, Sweden
- Founded
- 2018
- Employees
- 10
- Website
- amferia.com/
- Ownership
- Privately Held (backing)
Is this your company? Sign in with your work email to keep it current, or tell us what's wrong.